Brief: Galera Announces FDA Acceptance And Priority Review Of Avasopasem NDA
Feb 15 (Reuters) - Galera Therapeutics Inc GRTX.O :
* GALERA ANNOUNCES FDA ACCEPTANCE AND PRIORITY REVIEW OF
AVASOPASEM NDA FOR RADIOTHERAPY-INDUCED SEVERE ORAL MUCOSITIS
* GALERA THERAPEUTICS INC - PDUFA TARGET DATE OF AUGUST 9,
2023
Source text for Eikon: ID:nGNX1xhqhN
Further company coverage: GRTX.O
((Reuters.briefs@thomsonreuters.com;))
Recent news on Galera Therapeutics
See all newsBrief: Galera Therapeutics Says Nasdaq Will Delist Co's Common Stock By Filing Form 25 With SEC On Sept 4
Brief: Galera Announces Board Approval Of Complete Liquidation And Dissolution
Brief: Galera Therapeutics Receives Written Notice From Nasdaq Indicating That Nasdaq Hearings Panel Determined To Delist Co’s Shares
Brief: Alpha Pharma Investments Llc Reports 10.899% Passive Stake In Galera Therapeutics
Brief: Galera Adopts Limited Duration Stockholder Rights Agreement